Resonant Therapeutics announced the company has entered into an agreement with Janssen Research and Development with the aim to discover and validate novel tumor and immunological targets, and to validate certain therapeutic candidates. The collaboration leverages Resonant’s proprietary IMPaCT tumor microenvironment model and target validation platform and Janssen’s oncology capabilities to rapidly advance new targets and therapeutic opportunities.
“Resonant was launched to industrialize our tumor-microenvironment IMPaCT platform in order to efficiently discover, validate, and prioritize antibody therapeutics via a data-driven biological pipeline,” John K. Westwick, Ph.D., Resonant Founder and CEO said. “We are delighted to collaborate with industry-leader Janssen with the aim to help validate therapeutic candidates and novel functional tumor and immunological targets for difficult-to-treat cancers.”
Specific details of the agreement were not disclosed.